ESPE Abstracts

Background: GNRH agonist (GnRHa) has been widely used for decades to treat in patients with central precocious puberty (CPP). There are severe studies concerning changes in body composition in CPP patients following GnRHa treatment, but the results are inconsistent.

Objective and hypotheses: The aim of this study was to investigate the change of BMI in children treated with GnRHa for 2 years. Also, the present study was performed to assess whether BMI affects treatment outcomes.

Method: This study included 383 girls (214 CPP and 169 early puberty girls) were treated with depot leuprolide acetate monthly for at least 2 years. We analyzed the changes in BMI SDS. Furthermore, a single LH obtained 30 min after depot leuprolide acetate administration every 6 months to evaluate adequate hypothalamic–pituitary–gonadal axis suppression.

Results: Before the initiation of therapy, the girls with CPP had a mean BMI SDS for chronological age of 0.39±0.87. After 2 years of the treatment, mean BMI SDS was significantly increased (0.51±0.85, P<0.001). The frequency of overweight and obese patients increased from 22.4% to 27.4%. Single LH levels of 30 min after leuprolide injection at 2 years of treatment were not significantly different among normal weight, overweight, and obese subjects (0.32±1.83, 0.17±0.21, 0.12±0.09 IU/l, respectively, P=0.646 for all comparisons).

Conclusion: The BMI SDS for chronological age was significantly increased during treatment. Adequate education concerning lifestyle and diet during GnRHa treatment is needed.